The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Molecularly targeted therapy for malignant glioma
Abstract
Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. Understanding the molecular pathogenesis of glioma may lead to a rational development of new therapies. Despite the genetic heterogeneity of malignant gliomas, common aberrations in the signaling elements of the growth and survival pathways are found. New treatments have emerged to target molecules in these signaling pathways with the goal to increase specific efficacy and minimize toxicity. Monoclonal antibodies and low molecular‐weight kinase inhibitors are the most common classes of agents in targeted cancer treatment. Most clinical trials of these agents as monotherapies have failed to demonstrate survival benefit in unselected malignant glioma patient populations. Several mechanisms of treatment failure have been demonstrated. In response, multitargeted kinase inhibitors and combinations of single‐targeted kinase inhibitors have been developed to overcome therapeutic resistance. In addition, multimodality combinations of targeted agents with radiation, chemotherapy, or immunotherapy/vaccines may enhance treatment efficacy. Future development of these agents will require advances in discovery and validation of new molecular targets, improvement of therapeutic delivery, and identification of correlative biomarkers. Novel clinical trial designs and endpoints may increase the efficiency of new drug evaluation. In this review, the authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Self-citationPhase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Self-citationOutcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Self-citationGalanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 630
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
Mani, A., & Gelmann, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.081 · Cited by 549
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 442
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Self-citationHoughton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., & Traxler, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3344 · Cited by 323
Scott Ph.D., C. B., Scarantino M.D., P. D., Urtasun M.D., Movsas M.D., Jones M.D., Simpson M.D., Fischbach M.D., & Curran Jr., M. D. (1998) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00485-9 · Cited by 323
Ballman, K. V., Buckner, J. C., Brown, P. D., Giannini, C., Flynn, P. J., LaPlant, B. R., & Jaeckle, K. A. (2007) · Neuro-Oncology · doi:10.1215/15228517-2006-025 · Cited by 314
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas
Weaver, M., & Laske, D. W. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026246500788 · Cited by 299
Schueneman, A. J., Himmelfarb, E. A., Geng, L., Tan, J., Donnelly, E. F., Mendel, D. B., McMahon, G., & Hallahan, D. E. (2003) · PubMed · Cited by 259
Lassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K., Pao, W., Shih, A. H., Kuhn, J. G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0421 · Cited by 252
Modulation of radiation response by histone deacetylase inhibition
Chinnaiyan, P., Vallabhaneni, G., Armstrong, E., Huang, S.-M., & Harari, P. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.088 · Cited by 243
Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.101.4.1 · Cited by 243
Self-citationMacDonald, T. J., Taga, T., Shimada, H., Tabrizi, P., Zlokovic, B. V., Cheresh, D. A., & Laug, W. E. (2001) · Neurosurgery · doi:10.1097/00006123-200101000-00026 · Cited by 240
Wang, M. Y., Lu, K. V., Zhu, S., Dia, E. Q., Vivanco, I., Shackleford, G. M., Cavenee, W. K., Mellinghoff, I. K., Cloughesy, T. F., Sawyers, C. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4392 · Cited by 240
Yin, D., Zhou, H., Kumagai, T., Liu, G., Ong, J. M., Black, K. L., & Koeffler, H. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208225 · Cited by 232
Mamelak, A. N., Rosenfeld, S., Bucholz, R., Raubitschek, A., Nabors, L. B., Fiveash, J. B., Shen, S., Khazaeli, M. B., Colcher, D., Liu, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4569 · Cited by 218
Prados, M. D., Lamborn, K. R., Chang, S., Burton, E., Butowski, N., Malec, M., Kapadia, A., Rabbitt, J., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 218
Eshleman, J. S., Carlson, B. L., Mladek, A. C., Kastner, B. D., Shide, K. L., & Sarkaria, J. N. (2002) · PubMed · Cited by 198
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2215 · Cited by 191
Self-citationPelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
Momota, H., Nerio, E., & Holland, E. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1042 · Cited by 177
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
Dresemann, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi317 · Cited by 174
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
Doherty, L., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R., Zimmerman, J., Ostrowsky, L., & Wen, P. Y. (2006) · Neurology · doi:10.1212/01.wnl.0000223844.77636.29 · Cited by 168
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas
Knobbe-Thomsen, C. B., REIFENBERGER, J., & Reifenberger, G. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0929-9 · Cited by 156
Cloughesy, T. F., Wen, P. Y., Robins, H. I., Chang, S. M., Groves, M. D., Fink, K., Junck, L., Schiff, D., Abrey, L. E., Gilbert, M. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2323 · Cited by 154
Prognostic impact of molecular markers in a series of 220 primary glioblastomas
Houillier, C., Lejeune, J., Benouaich‐Amiel, A., Laigle–Donadey, F., Crinière, E., Mokhtari, K., Thillet, J., Delattre, J., Hoang‐Xuan, K., & Sanson, M. (2006) · Cancer · doi:10.1002/cncr.21819 · Cited by 144
Chakravarti, A., Dicker, A. P., & Mehta, M. P. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.092 · Cited by 138
New treatment strategies for malignant gliomas
Sathornsumetee, S., & Rich, J. N. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1087 · Cited by 135
Self-citationConrad, C., Friedman, H. S., Reardon, D. A., Provenzale, J., Jackson, E., Serajuddin, H., Laurent, D., Chen, B., & Yung, W. K. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.1512 · Cited by 112
Self-citationEller, J. L., Longo, S. L., Kyle, M. M., Bassano, D. A., Hicklin, D. J., & Canute, G. W. (2005) · Neurosurgery · doi:10.1227/01.neu.0000145865.25689.55 · Cited by 110
Sawada, M., Hadeishi, H., Suzuki, A., & Yasui, N. (2004) · Neurosurgery · doi:10.1227/01.neu.0000129551.64651.74 · Cited by 110
Rich, J. N., Sathornsumetee, S., Keir, S. T., Kieran, M. W., Laforme, A., Kaipainen, A., McLendon, R. E., Graner, M. W., Rasheed, B., Wang, X., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0319 · Cited by 97
Self-citationResults from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas
Fine, H. A., Kim, L., Royce, C., Draper, D., Haggarty, I., Ellinzano, H., Albert, P. S., Kinney, P., Musib, L. C., & Thornton, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1504 · Cited by 96
Rao, R. D., Mladek, A. C., Lamont, J. D., Goble, J. M., Erlichman, C., James, C. D., & Sarkaria, J. N. (2005) · Neoplasia · doi:10.1593/neo.05361 · Cited by 95
Krishnan, S., Brown, P. D., Ballman, K. V., Fiveash, J. B., Uhm, J. H., Giannini, C., Jaeckle, K. A., Geoffroy, F. J., Nabors, B., & Buckner, J. C. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.01.018 · Cited by 90
Reardon, D. A., Friedman, H. S., Yung, W. K. A., Brada, M., Conrad, C., Provenzale, J., Jackson, E., Serajuddin, H., Chen, B., & Laurent, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1513 · Cited by 90
Self-citationBrandes, A. A., Ermani, M., Turazzi, S., Scelzi, E., Berti, F., Amistà, P., Rotilio, A., Licata, C., & Fiorentino, M. V. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.645 · Cited by 84
EGFR tyrosine kinase domain mutations in human gliomas
Marie, Y., Carpentier, A. F., Omuro, A. M. P., Sanson, M., Thillet, J., Hoang‐Xuan, K., & Delattre, J. (2005) · Neurology · doi:10.1212/01.wnl.0000158654.07080.b0 · Cited by 79
Hui, A.-M., Zhang, W., Chen, W., Xi, D., Purow, B. W., Friedman, G. C., & Fine, H. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2740 · Cited by 74
Vogelbaum, M. A., Peereboom, D. M., Stevens, G. H. J., Barnett, G. H., & Brewer, C. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1558 · Cited by 72
Spence, A. M., Peterson, R. A., Scharnhorst, J., Silbergeld, D. L., & Rostomily, R. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000040837.68411.97 · Cited by 61
NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas
Lieberman, F. S., Cloughesy, T. F., Fine, H. A., Kuhn, J. G., Lamborn, K. R., Malkin, M. G., Robbins, H. I., Yung, W. A., Wen, P. Y., & Prados, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1510 · Cited by 58
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma
Geng, L., Shinohara, E. T., Kim, D., Tan, J., Osusky, K. L., Shyr, Y., & Hallahan, D. E. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.08.025 · Cited by 54
Reduced Glioma Infiltration in Src-deficient Mice
Lund, C. V., Nguyen, M. T. N., Owens, G. C., Pakchoian, A. J., Shaterian, A., Kruse, C. A., & Eliceiri, B. P. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9068-y · Cited by 53
Sathornsumetee, S., Hjelmeland, A. B., Keir, S. T., McLendon, R. E., Batt, D. B., Ramsey, T. M., Yusuff, N., Rasheed, B., Kieran, M. W., Laforme, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0284 · Cited by 52
Self-citationRaizer, J. J., Lassman, A. B., & Rossi, M. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1-cor · Cited by 50
Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
Wen, P. Y., Kesari, S., & Drappatz, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.733 · Cited by 40
Will Kinase Inhibitors Have a Dark Side?
Sawyers, C. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmcibr062354 · Cited by 35
Combining radiotherapy and angiogenesis inhibitors: Clinical trial design
Citrin, D. E., Ménard, C. M., & Camphausen, K. A. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.065 · Cited by 34
Gilbert, M. R., Gaupp, P., Liu, V., Conrad, C., Colman, H., Groves, M. D., Puduvalli, V. K., Levin, V. A., Hsu, S., Horowitz, J. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.1556 · Cited by 28
Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier
Bihorel, S., Camenisch, G., Groß, G., Lemaire, M., & Scherrmann, J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010975 · Cited by 19
Cited by
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Self-citation
Metadata
- Authors
- Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-06-15
- Volume
- 110
- Issue
- 1
- Pages
- 13-24
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2014994637
- Cited by
- 325
- References
- 77
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.